Valneva SE, a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza vaccine companies, for the marketing and distribution of Valneva’s three proprietary vaccines in Germany.

专注于特种疫苗的Valneva SE公司今天宣布，与全球最大的流感疫苗公司之一CSL Seqirus达成独家协议，将在德国营销和分销Valneva的三种 proprietary 疫苗。

Under the agreed terms, CSL Seqirus will start commercializing Valneva’s single-dose chikungunya vaccine IXCHIQ® from July 2025, and Valneva’s Japanese Encephalitis vaccine IXIARO® and cholera/ETEC1 vaccine DUKORAL® from January 2026. This new agreement with CSL Seqirus replaces the marketing and distribution agreement Valneva signed with Bavarian Nordic in 20212, which is due to conclude at the end of December 2025..

根据协议条款，CSL Seqirus将从2025年7月开始商业化Valneva的单剂量基孔肯雅病毒疫苗IXCHIQ®，并从2026年1月开始销售Valneva的日本脑炎疫苗IXIARO®和霍乱/ETEC疫苗DUKORAL®。该新协议取代了Valneva在2021年与Bavarian Nordic签署的营销和分销协议，后者将于2025年12月底到期。

The new agreement will last for three years and include minimum annual purchasing quantities and standard termination clauses based on change of control and non-performance.

新协议将持续三年，包含最低年度采购量以及基于控制权变更和未履行的标准化终止条款。

Dipal Patel, Chief Commercial Officer at Valneva, commented, “We are excited to join forces with CSL Seqirus to continue developing our commercial sales in Germany. CSL’s strong commercial presence in Germany will ensure seamless distribution of our vaccines in Europe’s largest travel vaccine market, which nicely complements our in-house commercial infrastructure focused on other key markets in Europe.”.

瓦尔内瓦公司首席商务官迪帕尔·帕特尔评论道：“我们很高兴与CSL Seqirus联手，继续在德国拓展我们的商业销售。CSL在德国的强大商业存在将确保我们的疫苗在欧洲最大的旅行疫苗市场中实现无缝分销，这很好地补充了我们专注于欧洲其他关键市场的内部商业基础设施。”

Valneva’s product sales reached €48.6 million in the first quarter of 2025, including €42.8 million from its proprietary vaccines. The Company expects product sales to grow to €170-180 million in 2025, driving positive cash flows for its overall commercial business3.

瓦尔内瓦的产品销售额在2025年第一季度达到4860万欧元，其中包括来自其专有疫苗的4280万欧元。公司预计2025年产品销售额将增长至1.7亿至1.8亿欧元，为其整体商业业务带来正现金流。

About Valneva SE

关于Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions..

我们是一家专业疫苗公司，致力于开发、生产和商业化针对未满足医疗需求的传染病预防疫苗。我们采取高度专业化和针对性的方法，运用我们在多种疫苗模式上的深厚专业知识，专注于提供第一、最佳或唯一的同类疫苗解决方案。

We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.

我们有着强大的业绩记录，已将多种疫苗从早期研发推进到获得批准，并且目前市场上有三种自主产权的旅行疫苗。

Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats.

我们不断增长的商业业务收入有助于推动我们疫苗管线的持续发展。这包括与辉瑞合作的唯一处于高级临床开发阶段的莱姆病疫苗候选药物、全球临床进展最快的志贺氏菌疫苗候选药物，以及针对寨卡病毒和其他全球公共卫生威胁的疫苗候选药物。

More information is available at www.valneva.com..

更多信息请访问 www.valneva.com。

Valneva Media and Investor Relations Contacts

Valneva媒体和投资者关系联系人

Laetitia Bachelot-Fontaine

拉艾蒂蒂娅·巴舍洛-方丹

VP Global Communications & European Investor Relations

全球传播与欧洲投资者关系副总裁

M +33 (0)6 4516 7099

M +33 (0)6 4516 7099

laetitia.bachelot-fontaine@valneva.com

拉埃蒂蒂娅·巴什洛-方丹@瓦尔内瓦.康姆

Joshua Drumm, Ph.D.

约书亚·德拉姆，博士

VP Global Investor Relations

全球投资者关系副总裁

M +001 917 815 4520

M +001 917 815 4520

joshua.drumm@valneva.com

约书亚·德鲁姆@瓦尔内瓦.康姆

Forward-Looking Statements

前瞻性声明

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to use and regulatory review of existing products. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future.

本新闻稿包含与Valneva业务相关的某些前瞻性声明，包括有关现有产品的使用和监管审查。此外，即使Valneva的实际结果或发展与其在本新闻稿中的前瞻性声明一致，这些结果或发展在未来可能无法持续。

In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements.

在某些情况下，您可以通过“可能”、“应该”、“也许”、“预期”、“预计”、“相信”、“意图”、“估计”、“目标”、“针对”或类似词语来识别前瞻性陈述。这些前瞻性陈述主要基于Valneva在本新闻稿发布当日的当前预期，并受许多已知和未知的风险、不确定性及其他因素影响，这些因素可能导致实际结果、表现或成就与此类前瞻性陈述中明示或暗示的任何未来结果、表现或成就存在重大差异。

In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results or new adverse events, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection.

特别是，Valneva的预期可能受到以下因素的影响，其中包括疫苗开发和生产过程中涉及的不确定性和延迟、意外的临床试验结果或新的不良事件、意外的监管行动或延迟、普遍的竞争、货币波动、全球及欧洲信贷危机的影响，以及获得或维持专利或其他专有知识产权保护的能力。

Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of.

临床前研究或早期临床试验的成功可能并不预示未来临床试验的结果。鉴于这些风险和不确定性，无法保证本新闻稿中所做的前瞻性陈述将会实现。Valneva 提供此信息截至。

Source: valneva.com

来源：valneva.com